Quantcast
Home > Quotes > NBY

NovaBay Pharmaceuticals, Inc. Common Stock (NBY) Quote & Summary Data

NBY 
$2.45
*  
0.1086
4.64%
Get NBY Alerts
*Delayed - data as of Jul. 17, 2018 11:37 ET  -  Find a broker to begin trading NBY now
Exchange:AMEX
Industry: Health Care
Community Rating:
View:    NBY Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
3.875
Today's High / Low
$ 2.45 / $ 2.45
Share Volume
176
90 Day Avg. Daily Volume
9,343
Previous Close
$ 2.3414
52 Week High / Low
$ 5 / $ 2
Market Cap
41,868,795
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.32

Intraday Chart

Shares Traded

Share Volume:
176
90 Day Avg. Daily Volume:
9,343

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.39

Trading Range

The current last sale of $2.45 is 22.50% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.45 $ 5
 Low: $ 2.45 $ 2

Company Description (as filed with the SEC)

NovaBay Pharmaceuticals, Inc. is a medical device company predominately focused on eye care. We are currently focused primarily on commercializing Avenova®, a prescription product sold in the United States for cleansing and removing foreign material including microorganisms and debris from skin around the eye, including the eyelid. Avenova is an eye care product formulated with our proprietary, stable and pure form of hypochlorous acid. Avenova has proven in laboratory testing to have broad antimicrobial properties as a preservative in solution as it removes foreign material including microorganisms and debris from the skin on the eyelids and lashes without burning or stinging. Our business strategy remains the same since November 2015, when we restructured our business to focus our resources on growing sales of Avenova in the United States. Our current three-part business strategy is comprised of: (1) focusing our resources on growing the U.S.  ... More ...  

Risk Grade

Where does NBY fit in the risk graph?


Risk Grade Scale

Consensus Recommendation

Analyst Info